...
首页> 外文期刊>Japanese journal of clinical oncology. >The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma
【24h】

The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma

机译:组蛋白脱乙酰化酶和p53表达和组织学亚型的组合在子宫平滑肌肉瘤中具有预后意义

获取原文
获取原文并翻译 | 示例

摘要

Objective: To investigate the expression of different histone deacetylases and their association with disease characteristics and survival outcomes in uterine leiomyosarcoma patients. Methods: The immunohistochemical expression of different histone deacetylases and p53 by tissue microarray and histological subtypes were assessed in tumor tissue samples of 42 eligible patients. Results: Histone deacetylases 1-4, 6 and 8 showed prevalent and strong (3+) expression (88.1, 90.5, 95.2, 92.9, 83.3 and 100%, respectively). Histone deacetylases 5, 7 and 9 showed infrequent strong expression (33.3, 50 and 38.1%, respectively). There were trends of higher disease-free survival rates according to the combination of weaker expression of histone deacetylase 5, 7 or 9 with positive p53 expression or with non-epithelial subtype. The patients with triple-positive favorable prognostic factors (any of weaker histone deacetylase 5, 7 and 9 expression, p53 positive, and non-epithelioid subtype) had the better survival outcomes while the patients with other combinations had the worse survival outcomes. In multivariate analysis, histone deacetylase 5 in combination with epithelioid subtype was an independent predictor for disease-free survival. Conclusions: Expression of histone deacetylase 5, 7 and 9 is a potential prognostic marker in uterine leiomyosarcoma when combined with pathologically relevant prognostic factors (p53 and histological subtype). This prevalent and strong histone deacetylase expression warrants further study in well-designed investigations of histone deacetylases as therapeutic targets in uterine leiomyosarcoma.
机译:目的:探讨不同组织脱乙酰酶的表达及其与子宫平滑肌肉瘤患者疾病特征及生存结果的表达。方法:在42名合格患者的肿瘤组织样品中评估不同组织脱乙酰酶和组织学亚型的不同组织脱乙酰酶和P53的免疫组织化学表达。结果:组蛋白脱乙酰酶1-4,6和8显示出普遍且强(3+)表达(88.1,90.5,95.2,92.9,83.3和100%)。组蛋白脱乙酰酶5,7和9分别显示出不常见的强烈表达(分别为33.3,50和38.1%)。根据具有阳性P53表达或非上皮亚型的组蛋白脱乙酰酶5,7或9的弱表达表达的组合或用非上皮亚型的组合存在较高的无病生存率趋势。三重阳性有利预后因子(任何较弱的组蛋白脱乙酰酶5,7和9表达,P53阳性和非上皮脲亚型)具有更好的存活结果,而其他组合的患者具有更差的存活结果。在多变量分析中,组蛋白脱乙酰酶5与上皮脲亚型组合是无疾病存活的独立预测因子。结论:组蛋白脱乙酰酶5,7和9的表达是组合在病理相关预后因子(P53和组织学亚型)中的子宫平滑肌肉瘤中的潜在预后标志物。这种普遍和强大的组蛋白脱乙酰酶表达可证是在设计良好的组蛋白脱乙酰酶的研究中进一步研究,作为子宫平滑肌肉瘤中的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号